BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.
BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces Read More »
Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for domestic drug manufacturing.
Generic Drug and API Manufacturers Call for Onshoring Incentives Read More »
Had Pfizer’s Freda Lewis-Hall not stepped in, SpringWorks’ rare disease treatment may never have reached patients. Pharmas can act now to help find the next Gomekli.
Pharma Is Sitting on Hidden Cures. Find Your “Freda” To Unlock Them Read More »
More than 30 organizations, including AdvaMed and the American Clinical Laboratory Association, are pushing for a permanent legislative solution to stop looming Medicare payment cuts for diagnostic tests.
Health groups urge passage of bill to ease Medicare pay cuts for tests Read More »
The CMS finalized the Medicare physician fee schedule for 2026 on Friday, one day before the statutory deadline. It includes an overall payment hike and a few policies that are deeply unpopular with specialists.
Medicare finalizes controversial cut to specialty care next year Read More »
At the center of the licensing deal is an NLRP3 inhibitor that has shown “encouraging efficacy in acute inflammation models,” according to TransThera, indicating its potential in various metabolic and inflammatory diseases.
Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal Read More »
Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital transformation, streamlined operations and strategic partnerships to navigate a turbulent market and global tariff pressures.
Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central nervous system.
Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold Read More »
The $600 million deal was foreshadowed during the company’s third quarter earnings call this month, when CEO Kevin Hammons said more hospital sales were in the works.
CHS inks deal to sell stake in Tennessee hospital to VUMC Read More »
A month after sparking optimism for patients with Huntington’s disease with highly positive data for AMT-130, uniQure revealed Monday that the FDA may be changing its tune on the evidence required for an approval application, a change of direction Stifel called “very challenging” for uniQure.
FDA Does ‘About-Face’ on UniQure’s Huntington’s Gene Therapy Read More »
